Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Hansoh Pharmaceutical Group Company Limited has entered into an exclusive licensing agreement with Guangzhou Lupeng Pharmaceutical Co., Ltd. to develop and commercialize the drug LP-168 in China. The agreement includes milestones and royalty payments that could total up to RMB729 million. LP-168, currently in Phase II clinical trials, is a promising treatment for non-tumor indications and is part of Hansoh’s strategic growth in the pharmaceutical industry.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.
